SeaStar Medical Holding Corp — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 68/100
What the filing says
SeaStar Medical reported Q2 2026 net revenue of $0.6M (vs. $0.3M in Q2 2025), driven by addition of 3 pediatric hospital customers to QUELIMMUNE, bringing total customer base to 20. Net loss widened to $3.7M in Q2 2026 from $2.0M in Q2 2025; cash fell to $7.0M (June 30, 2026) from $12.0M (Dec 31, 2025). NEUTRALIZE-AKI adult trial enrolled 223 of 339 patients; ICD-10-PCS billing codes effective October 1, 2026.
Why this rating
Revenue growth and regulatory milestones are positive, but accelerating cash burn (Q1+Q2 2026: $5.8M burned) and $7M cash balance at $7.3M market cap create existential funding risk requiring near-term capital raise.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.